Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASTEST Trial (rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time)
2019-003722-25Phase 3Active
- Sponsor
- University of Cincinnati
- Start
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in intracerebral hemorrhage (ICH) and brain hemorrhage (ICH) comparing eptacog alfa (activated) with placebo (2 arms). Primary endpoint: Primary functional outcome at 180 days. Started Aug 2020; status: active.
02
Drugs
coagulation factor VIIa
03
Conditions
intracerebral hemorrhage (ICH)brain hemorrhage (ICH)
Beyond the preview
Go deeper on 2019-003722-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003722-25.